These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28218867)

  • 41. Hepatocellular carcinoma after sustained viral response to interferon and ribavirin therapy in cirrhosis secondary to chronic hepatitis C.
    Khokhar N; Niazi TK; Qureshi MO
    J Coll Physicians Surg Pak; 2013 Oct; 23(10):699-702. PubMed ID: 24112253
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study.
    Stasi C; Piluso A; Arena U; Salomoni E; Montalto P; Monti M; Boldrini B; Corti G; Marra F; Laffi G; Milani S; Zignego AL
    World J Gastroenterol; 2015 Mar; 21(10):3013-9. PubMed ID: 25780300
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Taiwan consensus statement on the management of chronic hepatitis B.
    Chien RN; Kao JH; Peng CY; Chen CH; Liu CJ; Huang YH; Hu TH; Yang HI; Lu SN; Ni YH; Chuang WL; Lee CM; Wu JC; Chen PJ; Liaw YF
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):7-38. PubMed ID: 30527436
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection.
    Gray E; O'Leary A; Kieran JA; Fogarty E; Dowling T; Norris S;
    J Viral Hepat; 2016 Sep; 23(9):677-86. PubMed ID: 26996144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients.
    Joshi D; Carey I; Agarwal K
    Aliment Pharmacol Ther; 2013 Apr; 37(7):659-71. PubMed ID: 23432320
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    Intervirology; 2013; 56(1):37-45. PubMed ID: 23037768
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Hepatitis C: the recovery].
    Marcellin P
    Gastroenterol Clin Biol; 2009; 33(8-9):819-29. PubMed ID: 19541439
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G; Tolvaj G; Halász T; Stotz G
    Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiviral treatment and liver-related complications in hepatitis delta.
    Wranke A; Serrano BC; Heidrich B; Kirschner J; Bremer B; Lehmann P; Hardtke S; Deterding K; Port K; Westphal M; Manns MP; Cornberg M; Wedemeyer H
    Hepatology; 2017 Feb; 65(2):414-425. PubMed ID: 27770553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection.
    Weiler N; Zeuzem S; Welker MW
    World J Gastroenterol; 2016 Nov; 22(41):9044-9056. PubMed ID: 27895394
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
    Vachon ML; Dieterich DT
    Semin Liver Dis; 2011 Nov; 31(4):399-409. PubMed ID: 22189979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
    Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P
    Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy.
    Babatin M; Schindel L; Burak KW
    Can J Gastroenterol; 2005 Jun; 19(6):359-65. PubMed ID: 15997269
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Hepatitis C treatment in special patient groups].
    Berenguer M; Jorquera F; Ángel Serra M; Sola R; Castellano G
    Gastroenterol Hepatol; 2014 Jul; 37 Suppl 1():23-36. PubMed ID: 25907435
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
    Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V
    Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Hepatitis C].
    Moradpour D; Blum HE
    Ther Umsch; 2004 Aug; 61(8):493-8. PubMed ID: 15457965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.